Thursday, October 15, 2026
ExploreSearch
Finance Via News

Corporate Valuation

2 articles

10-Year Treasury Yield Climbing Toward 5% Splits AI Sector Into Valuation Winners and Losers

10-Year Treasury Yield Climbing Toward 5% Splits AI Sector Into Valuation Winners and Losers

The 10-Year US Treasury yield has moved from 4.58 toward 5.0, raising discount rates across equity markets. Unprofitable AI infrastructure firms face the steepest valuation pressure, while profitable AI enterprise software companies with near-term cash flows remain more insulated. Global rate pressure is compounding the effect, with Japanese 10-Year bond yields jumping from 2.478 to 2.807.

LM Salvado•
Tesla Valuation Driven by AI Narrative Over EV Fundamentals, Analysts Say

Tesla Valuation Driven by AI Narrative Over EV Fundamentals, Analysts Say

Tesla's stock pricing reflects investor focus on AI optionality—autonomous driving, robotics, energy software—rather than core electric vehicle sales. UBS recently upgraded Tesla after raising its price target, citing long-term opportunities balancing near-term EV demand challenges. Analyst Joseph Spak notes the stock trades on sentiment and momentum, creating persistent volatility and divergence between traditional auto analysts and tech-focused investors.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com